Dr. Rafael Correa-Rocha, CSO of ThyTech, participated for the second consecutive year as an invited speaker at the 8th Treg-Directed Therapies Summit 2026 in Boston, where he presented clinical advances of the thyTregs™ cell therapy, featured as one of the event’s highlighted sessions.

ThyTech showcased favorable results in pediatric heart transplant patients and progress in developing an allogeneic version to expand its application to other immune-mediated diseases. The technology, based on pediatric thymic tissue, aims to induce immune tolerance and reduce reliance on chronic immunosuppressive treatments.

The summit brought together leading international biopharma and academic stakeholders, and ThyTech’s participation comes at a time of growing recognition for Treg therapies, reinforced by the 2025 Nobel Prize in Medicine. This further positions the company as a relevant global player in immunomodulatory cell therapies.

More info: europapress.com